|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2012显示文摘 | R. Phillip Dellinger Mitchell M. Levy Andrew Rhodes Djillali Annane Herwig Gerlach Steven M. Opal Jonathan E. Sevransky Charles L. Sprung Ivor S. Douglas Roman Jaeschke Tiffany M. Osborn Mark E. Nunnally Sean R. Townsend Konrad Reinhart Ruth M. Kleinpell | 2013 | Critical Care Medicine2013，，2： | 12 |
| 2 | Stem Cell Ophthalmology Treatment Study (SCOTS): bone marrow-derived stem cells in the treatment of Leber's hereditary optic neuropathy显示文摘The Stem Cell Ophthalmology Treatment Study(SCOTS) is currently the largest-scale stem cell ophthalmology trial registered at Clinical Trials.gov(identifier: NCT01920867). SCOTS utilizes autologous bone marrow-derived stem cells(BMSCs) to treat optic nerve and retinal diseases. Treatment approaches include a combination of retrobulbar, subtenon, intravitreal, intra-optic nerve, subretinal, and intravenous injection of autologous BMSCs according to the nature of the disease, the degree of visual loss, and any risk factors related to the treatments. Patients with Leber's hereditary optic neuropathy had visual acuity gains on the Early Treatment Diabetic Retinopathy Study(ETDRS) of up to 35 letters and Snellen acuity improvements from hand motion to 20/200 and from counting fingers to 20/100. Visual field improvements were noted. Macular and optic nerve head nerve fiber layer typically thickened. No serious complications were seen. The increases in visual acuity obtained in our study were encouraging and suggest that the use of autologous BMSCs as provided in SCOTS for ophthalmologic mitochondrial diseases including Leber's hereditary optic neuropathy may be a viable treatment option. | Jeffrey N. Weiss Steven Levy Susan C. Benes | 2016 | Neural Regeneration Research2016，11，10： | 10 |
| 3 | Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012显示文摘 | R. P. Dellinger Mitchell M. Levy Andrew Rhodes Djillali Annane Herwig Gerlach Steven M. Opal Jonathan E. Sevransky Charles L. Sprung Ivor S. Douglas Roman Jaeschke Tiffany M. Osborn Mark E. Nunnally Sean R. Townsend Konrad Reinhart Ruth M. Kleinpell Derek | 2013 | Intensive Care Medicine2013，，2： | 7 |
| 4 | 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference显示文摘 | Mitchell M. Levy Mitchell P. Fink John C. Marshall Edward Abraham Derek Angus Deborah Cook Jonathan Cohen Steven M. Opal Jean-Louis Vincent Graham Ramsay | 2003 | Critical Care Medicine2003，，4： | 7 |
| 5 | Stem Cell Ophthalmology Treatment Study(SCOTS) for retinal and optic nerve diseases: a case report of improvement in relapsing auto-immune optic neuropathy显示文摘We present the results from a patient with relapsing optic neuropathy treated within the Stem Cell Ophthalmology Treatment Study(SCOTS). SCOTS is an Institutional Review Board approved clinical trial and has become the largest ophthalmology stem cell study registered at the National Institutes of Health to date(www.clinicaltrials.gov Identifier NCT 01920867). SCOTS utilizes autologous bone marrow-derived stem cells(BMSCs) for treatment of retinal and optic nerve diseases. Pre-treatment and post-treatment comprehensive eye exams of a 54 year old female patient were performed both at the Florida Study Center, USA and at The Eye Center of Columbus, USA. As a consequence of a relapsing optic neuritis, the patient's previously normal visual acuity decreased to between 20/350 and 20/400 in the right eye and to 20/70 in the left eye. Significant visual field loss developed bilaterally. The patient underwent a right eye vitrectomy with injection of BMSCs into the optic nerve of the right eyeand retrobulbar, subtenon and intravitreal injection of BMSCs in the left eye. At 15 months after SCOTS treatment, the patient's visual acuity had improved to 20/150 in the right eye and 20/20 in the left eye. Bilateral visual fields improved markedly. Both macular thickness and fast retinal nerve fiber layer thickness were maximally improved at 3 and 6 months after SCOTS treatment. The patient also reduced her mycophenylate dose from 1,500 mg per day to 500 mg per day and required no steroid pulse therapy during the 15-month follow up. | Jeffrey N.Weiss Steven Levy Susan C.Benes | 2015 | Neural Regeneration Research2015，10，9： | 6 |
| 6 | 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference显示文摘 | Mitchell M. Levy Mitchell P. Fink John C. Marshall Edward Abraham Derek Angus Deborah Cook Jonathan Cohen Steven M. Opal Jean-Louis Vincent Graham Ramsay | 2003 | Critical Care Medicine2003，，4： | 6 |
| 7 | Stem Cell Ophthalmology Treatment Study(SCOTS) for retinal and optic nerve diseases: a preliminary report显示文摘In this report, we present the results of a single patient with optic neuropathy treated within the Stem Cell Ophthalmology Treatment Study(SCOTS). SCOTS is an Institutional Review Board approved clinical trial and is the largest ophthalmology stem cell study registered at the National Institutes of Health to date- www.clinicaltrials.gov Identifier NCT 01920867. SCOTS utilizes autologous bone marrow-derived stem cells in the treatment of optic nerve and retinal diseases. Pre- and post-treatment comprehensive eye exams were independently performed at the Wilmer Eye Institute at the Johns Hopkins Hospital, USA. A 27 year old female patient had lost vision approximately 5 years prior to enrollment in SCOTS. Pre-treatment best-corrected visual acuity at the Wilmer Eye Institute was 20/800 Right Eye(OD) and 20/4,000 Left Eye(OS). Four months following treatment in SCOTS, the central visual acuity had improved to 20/100 OD and 20/40 OS. | Jeffrey N.Weiss Steven Levy Alexis Malkin | 2015 | Neural Regeneration Research2015，10，6： | 5 |
| 8 | 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference显示文摘 | Mitchell M. Levy Mitchell P. Fink John C. Marshall Edward Abraham Derek Angus Deborah Cook Jonathan Cohen Steven M. Opal Jean-Louis Vincent Graham Ramsay | 2003 | Intensive Care Medicine2003，，4： | 3 |
| 9 | Stem Cell Ophthalmology Treatment Study (SCOTS): improvement in serpiginous choroidopathy following autologous bone marrow derived stem cell treatment显示文摘We report results in a 77-year-old male patient with visual loss from long-standing serpiginous choroidopathy treated with bone marrow derived stem cells(BMSC) within the Stem Cell Ophthalmology Treatment Study(SCOTS).SCOTS is an Institutional Review Board approved clinical trial and the largest ophthalmology stem cell study registered at the National Institutes of Health to date(Clinical Trials.gov Identifier: NCT01920867).Eight months after treatment by a combination of retrobulbar,subtenon,intravitreal and intravenous injection of BMSC,the patient's best corrected Snellen acuity improved from 20/80–to 20/60+1in the right eye and from 20/50–to 20/20–3 in the left eye.The Early Treatment of Diabetic Retinopathy Study(ETDRS) visual acuity continued to improve over the succeeding 8 months and the optical coherence tomography macular volume increased.The increases in visual acuity and macular volume are encouraging and suggest that the use of BMSC as provided in SCOTS may be a viable approach to treating serpiginous choroidopathy. | Jeffrey N. Weiss Susan C. Benes Steven Levy | 2016 | Neural Regeneration Research2016，11，9： | 3 |
| 10 | Histologic and Imaging Features of Mural Nodules in Mucinous Pancreatic Cysts显示文摘 | Ning Zhong Lizhi Zhang Naoki Takahashi Vladislav Shalmiyev Marcia Irene Canto Jonathan E. Clain John C. Deutsch John DeWitt Mohamad A. Eloubeidi Ferga C. Gleeson Michael J. Levy Shawn Mallery Massimo Raimondo Elizabeth Rajan Tyler Stevens Mark Topazian | 2012 | Clinical Gastroenterology and Hepatology2012，，2： | 2 |
| 11 | Macrophage-specific inhibition of the histone demethylase JMJD3 decreases STING and pathologic inflammation in diabetic wound repair显示文摘Macrophage plasticity is critical for normal tissue repair following injury.In pathologic states such as diabetes,macrophage plasticity is impaired,and macrophages remain in a persistent proinflammatory state;however,the reasons for this are unknown.Here,using single-cell RNA sequencing of human diabetic wounds,we identified increased JMJD3 in diabetic wound macrophages,resulting in increased inflammatory gene expression.Mechanistically,we report that in wound healing,JMJD3 directs early macrophage-mediated inflammation via JAK1,3/STAT3 signaling.However,in the diabetic state,we found that IL-6,a cytokine increased in diabetic wound tissue at later time points post-injury,regulates JMJD3 expression in diabetic wound macrophages via the JAK1,3/STAT3 pathway and that this late increase in JMJD3 induces NFκB-mediated inflammatory gene transcription in wound macrophages via an H3K27me3 mechanism.Interestingly,RNA sequencing of wound macrophages isolated from mice with JMJD3-deficient myeloid cells(Jmjd3f/fLyz2Cre+)identified that the STING gene(Tmem173)is regulated by JMJD3 in wound macrophages.STING limits inflammatory cytokine production by wound macrophages during healing.However,in diabetic mice,its role changes to limit wound repair and enhance inflammation.This finding is important since STING is associated with chronic inflammation,and we found STING to be elevated in human and murine diabetic wound macrophages at late time points.Finally,we demonstrate that macrophage-specific,nanoparticle inhibition of JMJD3 in diabetic wounds significantly improves diabetic wound repair by decreasing inflammatory cytokines and STING.Taken together,this work highlights the central role of JMJD3 in tissue repair and identifies cell-specific targeting as a viable therapeutic strategy for nonhealing diabetic wounds. | Christopher O.Audu William J.Melvin Amrita D.Joshi Sonya J.Wolf Jadie Y.Moon Frank M.Davis Emily C.Barrett Kevin D.Mangum Hongping Deng Xianying Xing Rachel Wasikowski Lam C.Tsoi Sriganesh B.Sharma Tyler M.Bauer James Shadiow Matthew A.Corriere Andrea TObi Steven LKunkel Benjamin Levi Bethany BMoore Johann EGudjonsson Andrew MSmith Katherine A.Gallagher | 2022 | Cellular & Molecular Immunology2022，19，11： | 2 |
| 12 | Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012显示文摘 | R. P. Dellinger Mitchell M. Levy Andrew Rhodes Djillali Annane Herwig Gerlach Steven M. Opal Jonathan E. Sevransky Charles L. Sprung Ivor S. Douglas Roman Jaeschke Tiffany M. Osborn Mark E. Nunnally Sean R. Townsend Konrad Reinhart Ruth M. Kleinpell Derek | 2013 | Intensive Care Medicine2013，，2： | 2 |
| 13 | 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference显示文摘 | Mitchell M. Levy Mitchell P. Fink John C. Marshall Edward Abraham Derek Angus Deborah Cook Jonathan Cohen Steven M. Opal Jean-Louis Vincent Graham Ramsay | 2003 | Intensive Care Medicine2003，，4： | 1 |
| 14 | Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2012显示文摘 | R. Phillip Dellinger Mitchell M. Levy Andrew Rhodes Djillali Annane Herwig Gerlach Steven M. Opal Jonathan E. Sevransky Charles L. Sprung Ivor S. Douglas Roman Jaeschke Tiffany M. Osborn Mark E. Nunnally Sean R. Townsend Konrad Reinhart Ruth M. Kleinpell | 2013 | Critical Care Medicine2013，，2： | 1 |
| 15 | Dietary n · 3 polyunsaturated tatty acids decrease hepatic triglycefides in Fischer 344 rates 显示文摘 | Levy JR Clare JN Stevens W | 2004 | Hepatology2004，39，3： | 1 |
| 16 | Dietary n-3 polyunsaturatde fattyacids decrease hepatic triglycefides in Fischer 344 rates显示文摘 | LEVY J CLARE J N STEVENS W | 2004 | Hepatology2004，39，3： | 1 |
| 17 | 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference显示文摘 | Mitchell M. Levy Mitchell P. Fink John C. Marshall Edward Abraham Derek Angus Deborah Cook Jonathan Cohen Steven M. Opal Jean-Louis Vincent Graham Ramsay | 2003 | Critical Care Medicine2003，，4： | 1 |
| 18 | Dietary n-3 polyunsaturated fatty acids decrease hepatic triglycerides in Fischer 344 rats显示文摘 | Levy J R Clore J N Stevens W | 2004 | Hepatology2004，39，3： | 1 |
| 19 | Measurement, modeling, and analysis of a peer-to-peer file-sharing workload显示文摘 | Krishna P. Gummadi Richard J. Dunn Stefan Saroiu Steven D. Gribble Henry M. Levy John Zahorjan | 2003 | ACM SIGOPS Operating Systems Review2003，，5： | 1 |
| 20 | Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2012显示文摘 | R. Phillip Dellinger Mitchell M. Levy Andrew Rhodes Djillali Annane Herwig Gerlach Steven M. Opal Jonathan E. Sevransky Charles L. Sprung Ivor S. Douglas Roman Jaeschke Tiffany M. Osborn Mark E. Nunnally Sean R. Townsend Konrad Reinhart Ruth M. Kleinpell | 2013 | Critical Care Medicine2013，，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员